Senator Roberts, I think I've explained the principle, which is that from time to time we know that shortages of pharmaceuticals do arise. They arise because of interruptions to global supply chains or, sometimes, an interruption in a particular facility's manufacturing capability. That disruption doesn't immediately translate into a shortage, but we know, logically, that it will at some moment. These provisions allow us to get ahead of that situation.